Subbaramaiah Kotha, Hudis Clifford, Chang Sung-Hee, Hla Timothy, Dannenberg Andrew J
Department of Medicine, Weill Cornell Medical College, New York, New York 10065.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065.
J Biol Chem. 2008 Feb 8;283(6):3433-3444. doi: 10.1074/jbc.M705409200. Epub 2007 Dec 14.
Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens. Because aromatase-dependent estrogen biosynthesis has been linked to hormone-dependent breast carcinogenesis, it is important to elucidate the mechanisms that regulate CYP19 gene expression. The main objective of this study was to identify the receptors (EP) for prostaglandin E(2) (PGE(2)) that mediate the induction of CYP19 transcription in human adipocytes and breast cancer cells. Treatment with PGE(2) induced aromatase, an effect that was mimicked by either EP(2) or EP(4) agonists. Antagonists of EP(2) or EP(4) or small interference RNA-mediated down-regulation of these receptors suppressed PGE(2)-mediated induction of aromatase. PGE(2) via EP(2) and EP(4) stimulated the cAMP-->protein kinase A pathway resulting in enhanced interaction between P-CREB, p300, and the aromatase promoter I.3/II. Overexpressing a mutant form of p300 that lacks histone acetyltransferase activity suppressed PGE(2)-mediated induction of aromatase promoter activity. PGE(2) via EP(2) and EP(4) also caused a reduction in both the amounts of BRCA1 and the interaction between BRCA1 and the aromatase promoter I.3/II. Activation of the aromatase promoter by PGE(2) was suppressed by overexpressing wild-type BRCA1. Silencing of EP(2) or EP(4) also blocked PGE(2)-mediated induction of the progesterone receptor, a prototypic estrogen-response gene. In a mouse model, overexpressing COX-2 in the mammary gland, a known inducer of PGE(2) synthesis, led to increased aromatase mRNA and activity and reduced amounts of BRCA1; these effects were reversed by knocking out EP(2). Taken together, these results suggest that PGE(2) via EP(2) and EP(4) activates the cAMP-->PKA-->CREB pathway leading to enhanced CYP19 transcription and increased aromatase activity. Reciprocal changes in the interaction between BRCA1, p300, and the aromatase promoter I.3/II contributed to the inductive effects of PGE(2).
细胞色素P450芳香化酶(芳香化酶)是CYP19基因的产物,可催化雄激素合成雌激素。由于芳香化酶依赖性雌激素生物合成与激素依赖性乳腺癌发生有关,因此阐明调节CYP19基因表达的机制很重要。本研究的主要目的是鉴定介导人脂肪细胞和乳腺癌细胞中CYP19转录诱导的前列腺素E2(PGE2)受体(EP)。用PGE2处理可诱导芳香化酶,EP2或EP4激动剂可模拟这种效应。EP2或EP4拮抗剂或小干扰RNA介导的这些受体下调可抑制PGE2介导的芳香化酶诱导。PGE2通过EP2和EP4刺激cAMP→蛋白激酶A途径,导致P-CREB、p300与芳香化酶启动子I.3/II之间的相互作用增强。过表达缺乏组蛋白乙酰转移酶活性的p300突变体可抑制PGE2介导的芳香化酶启动子活性诱导。PGE2通过EP2和EP4还导致BRCA1的量以及BRCA1与芳香化酶启动子I.3/II之间的相互作用减少。过表达野生型BRCA1可抑制PGE2对芳香化酶启动子的激活。沉默EP2或EP4也可阻断PGE2介导的孕激素受体(一种典型的雌激素反应基因)的诱导。在小鼠模型中,在乳腺中过表达COX-2(一种已知的PGE2合成诱导剂)可导致芳香化酶mRNA和活性增加以及BRCA1量减少;通过敲除EP2可逆转这些效应。综上所述,这些结果表明PGE2通过EP2和EP4激活cAMP→PKA→CREB途径,导致CYP19转录增强和芳香化酶活性增加。BRCA1、p300与芳香化酶启动子I.3/II之间相互作用的相互变化促成了PGE2的诱导作用。